|Articles|September 1, 2014

June 2014 BPA Brand Report

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

What Impact will DTC Programs have on Generic Drug Prices?

ByMike Hollan,Chris O'Dell

October 29th 2025

What Impact will FDA's ANDA Prioritization Pilot have on the Global Supply Chain?

ByMike Hollan,Marcel Botha

October 29th 2025

Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns

ByNicholas Jacobus

October 28th 2025

GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate

ByNicholas Jacobus

October 28th 2025

Image Credit: Adobe Stock Images/David A Litman

FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis

ByDavy James

October 28th 2025

June 2014 BPA Brand Report

Newsletter

Related Content

What Impact will DTC Programs have on Generic Drug Prices?

What Impact will FDA's ANDA Prioritization Pilot have on the Global Supply Chain?

Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns

GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate

FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis

Trending on PharmExec

Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns

FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis

GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate

FDA Expands Indication for Merck’s Winrevair in Pulmonary Arterial Hypertension

Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales